

National Institute for Health and Clinical Excellence

Single Technology Appraisal

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Royal College of Nursing

Introduction

The Royal College of Nursing was invited to comment on the Appraisal Consultation Document (ACD) of the technology appraisal of Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Nurses caring for osteoporosis patients reviewed this document on behalf of the RCN.

The RCN welcomes the opportunity to comment on this document and responds below to the four questions on which comments were requested:

Appraisal Consultation Document – RCN Response

The Royal College of Nursing welcomes the opportunity to review the Appraisal Consultation Document (ACD) of the technology appraisal of Denosumab for the prevention of osteoporotic fractures in postmenopausal women. The RCN's response to the four questions on which comments were requested is set out below:

i) **Has the relevant evidence been taken into account?**

This seems comprehensive and we are not aware of any new information that should be considered.

ii) **Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence, and are the preliminary views on the resource impact and implications for the NHS appropriate?**

The summaries seem reasonable interpretations of the evidence. The preliminary views on the resource impact and implications for the NHS seem appropriate.

- iii) **Are the provisional recommendations of the Appraisal Committee sound and do they constitute a suitable basis for the preparation of guidance to the NHS?**

The provisional recommendations of the Appraisal Committee appear suitable basis for preparation of guidance to the NHS.

- iv) **Are there any equality related issues that need special consideration that are not covered in the ACD?**

None that we are aware of at this stage. We would however, ask that any guidance issued should show that equality issues have been considered and that the guidance demonstrates an understanding of issues concerning patients' age, faith, race, gender, disability, cultural and sexuality where appropriate.